Chronic gastritis with Helicobacter pylori infection
Conditions
Interventions
Vonoprazan 40mg, ABPC 1500mg, CAM 400mg, for the first 7days, with all drugs given twice daily
Esomeprazole 40mg, ABPC 1500mg, CAM 400mg, for the first 7 days, with all drugs given twice daily
Sponsors
Takamatsu Redcross Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who received a diagnosis of Helicobacter pylori gastritis by any one method of a rapid urease test, a urea breath test, a blood antibody test, a stool antigen test, and microbial culture.
Exclusion criteria
Exclusion criteria: 1. Patients who suggested or received a diagnosis of other infectious diseases. 2. Patients who received a diagnosis of acute gastritis, advanced gastric cancer, gastric MALT lymphoma, and postgastrectomy by endoscopic examination. 3. Patients who have coexisting severe heart disease, liver disease, renal disease, respiratory disease, metabolic disease, and neuromuscular disease. 4. Patients who received any one of lansoprazole, esomeprazole, omeprazole, and vonoprazan within 2 weeks. 5. Patients who have histories of eradication therapy for Helicobacter pylori. 6. Patients who have a past history of allergy for vonoprazan, esomeprazole, amoxicillin, clarithromycin, and metronidazor. 7. Pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rate of the first-line therapy assessed by a urea breath test from 6 to 10 weeks after cessation of therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Eradication rate of second-line therapy with vonoprazan in the patients who failed first-line therapy. | — |
Countries
Japan
Contacts
Public ContactHiroyuki Tamaki
Takamatsu Redcross Hospital Gastroenterology
Outcome results
None listed